Mylan Bids Nearly $30 Billion For Perrigo In Generic Market Consolidation Move
This article was originally published in The Tan Sheet
Executive Summary
Perrigo receives an unsolicited offer from Mylan for almost $30 billion in cash and stock, the firms say. The deal, which would create an OTC, nutritional product and generic Rx drug firm with 2014 revenue of $15.3 billion, could launch a bidding war with other firms vying for Dublin-based Perrigo, say analysts.